Serum Levels of Intercellular Adhesion Molecule-1 in Squamous Cell Carcinoma of the Head and Neck

Tumor Biology ◽  
1997 ◽  
Vol 18 (2) ◽  
pp. 88-94 ◽  
Author(s):  
B. Wollenberg ◽  
N. v. Jan ◽  
W. Sautier ◽  
K. Hofmann ◽  
U.M. Schmitt ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Adhesion Molecule ◽  
Serum Levels ◽  
Intercellular Adhesion ◽  
Intercellular Adhesion Molecule ◽  
Intercellular Adhesion Molecule 1

Nerve cell adhesion molecule expression in squamous cell carcinoma of the head and neck: A predictor of propensity toward perineural spread

1999 ◽  
Vol 109 (5) ◽  
pp. 821-826 ◽  
Author(s):  
Robert B. McLaughlin ◽  
Kathleen T. Montone ◽  
Stephen J. Wall ◽  
Ara A. Chalian ◽  
Gregory S. Weinstein ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Adhesion ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Nerve Cell ◽  
Squamous Cell ◽  
Adhesion Molecule ◽  
Cell Adhesion Molecule ◽  
Adhesion Molecule Expression ◽  
Perineural Spread

Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system

1998 ◽  
Vol 4 (1) ◽  
pp. 39-44 ◽  
Author(s):  
M Trojano ◽  
C Avolio ◽  
M Ruggieri ◽  
F De Robertis ◽  
F Giuliani ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Nervous System ◽  
Adhesion Molecule ◽  
Serum Levels ◽  
Intercellular Adhesion ◽  
Demyelinating Diseases ◽  
Intercellular Adhesion Molecule ◽  
Intercellular Adhesion Molecule 1 ◽  
Mean Values ◽  
Soluble Intercellular Adhesion Molecule

Serum and cerebrospinal fluid (CSF) soluble Intercellular adhesion molecule-1 (ICAM-1) levels were evaluated (ELISA) in 22 untreated and 13 corticosteroid-treated active relapsing remitting (RR) Multiple Sclerosis (MS), in 10 untreated and 10 corticosteroid-treated Guillain-Barré syndrome (GBS) and in 17 non-inflammatory neurological diseases (NIND). Twenty-eight clinically inactive RR MS were assayed for serum sICAM-1 before and after 3 months treatment of 8 MIU rIFNb-1b taken s.c. every other day. High sICAM-1 serum levels above the NIND values were found in untreated clinically active MS and in untreated GBS (P50.05) but not in the untreated clinically inactive MS group. The active MS group showed significantly (P=0.0001) higher sICAM-1 serum levels if compared to the inactive group. Corticosteroid-treated active MS and GBS patients showed lower (P50.05) serum sICAM-1 levels than the corresponding untreated groups. Serum sICAM-1 levels after 3 months of rIFNb-1b treatment (P50.0001, paired t-test) resulted increased compared to pretreatment values in MS. The mean values of CSF/serum sICAM-1: CSF/serum Albumin ratios (sICAM-1 Index) in active untreated MS patients were higher compared to NIND (P50.005) and to corticosteroid-treated MS group (P=0.01). sICAM Index values in GBS did not differ from those in NIND. The results seem to suggest potential roles for serum sICAM-1 in downregulating the ongoing inflammatory response at the blood-brain barrier level and for CSF sICAM-1 in the maintenance of a central nervous system local immune response.

Sign in / Sign up

Export Citation Format

Share Document